Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.74 USD | -0.36% | -1.79% | +65.06% |
Business Summary
Number of employees: 28
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joel Lewis
CEO | Chief Executive Officer | 54 | 17-11-30 |
Jack Callicutt
DFI | Director of Finance/CFO | 56 | 13-06-30 |
Ezra R. lowe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Pol Boudes
CTO | Chief Tech/Sci/R&D Officer | 67 | 20-03-01 |
Harold Shlevin
BRD | Director/Board Member | 75 | 12-09-30 |
Susan Thornton
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kevin Freeman
BRD | Director/Board Member | 62 | 11-04-30 |
Benjamin Carson
BRD | Director/Board Member | 73 | Dec. 06 |
Gil Omenn
BRD | Director/Board Member | 83 | 14-09-22 |
Gilbert Amelio
BRD | Director/Board Member | 81 | 09-02-11 |
Harold Shlevin
BRD | Director/Board Member | 75 | 12-09-30 |
Dick Uihlein
CHM | Chairman | 79 | 17-12-13 |
Marc Rubin
BRD | Director/Board Member | 69 | 11-10-11 |
Kary Eldred
BRD | Director/Board Member | 50 | 17-12-31 |
Richard Zordani
BRD | Director/Board Member | 52 | 20-08-31 |
Elissa Schwartz
BRD | Director/Board Member | 54 | 20-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,235,000 | 0 | 0 | 67.65 % |
Stock B | 1 | 62,148,134 | 42,881,405 ( 69.00 %) | 0 | |
Stock C | 0 | 176 | 0 | 0 |
Company contact information
Galectin Therapeutics, Inc.
4960 Peachtree Industrial Boulevard Suite 240
30071, Norcross
+(678) 620-3186
http://www.galectintherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.76% | 170M | |
+55.59% | 55.7B | |
+41.08% | 39.91B | |
-5.70% | 39.57B | |
-5.56% | 28.16B | |
+15.93% | 26.3B | |
-21.15% | 18.94B | |
+32.82% | 12.17B | |
+26.02% | 12.12B | |
+2.39% | 12.12B |
- Stock Market
- Equities
- GALT Stock
- Company Galectin Therapeutics Inc.